Lauren E. Strelec

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Anthony R. Mato, Chadi Nabhan, Paul M. Barr et al. · Blood · 2016 · 187 citations · Full text

R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

Nirav N. Shah, Anikó Szabó, Scott F. Huntington et al. · British Journal of Haematology · 2017 · 96 citations · Full text

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg et al. · Haematologica · 2020 · 51 citations · Full text

Immunology, Pathology, Metronomic Chemotherapy +18

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis

Steven M. Bair, Lauren E. Strelec, Tatyana Feldman et al. · The Oncologist · 2018 · 40 citations · Full text

Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis

Steven M. Bair, Lauren E. Strelec, Sarah Nagle et al. · American Journal of Hematology · 2017 · 32 citations · Full text

Cell Therapy, Relapsed/refractory Hodgkin Lymphoma, Immunology +20